Clarity Pharmaceuticals Sees Positive Results in Cancer Trial

Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.

Clarity Pharmaceuticals has reported promising results from its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSMA, showing favorable safety profiles and significant reductions in prostate-specific antigen levels among participants. The Expanded Access Program also demonstrated noteworthy outcomes, with patients achieving complete responses and substantial PSA reductions after multiple doses. These findings highlight the potential of flexible dosing regimens in treating metastatic castration-resistant prostate cancer.

For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.